Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2WEINREICH, David M; ROSENBERG, Steven A.Journal of immunotherapy (1997). 2002, Vol 25, Num 2, pp 185-187, issn 1524-9557Article

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian CancerKARLAN, Beth Y; OZA, Amit M; COVENS, Allan et al.Journal of clinical oncology. 2012, Vol 30, Num 4, pp 362-371, issn 0732-183X, 10 p.Article

Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude miceWEINREICH, David M; ELARAJ, Dina M; PUHLMANN, Markus et al.Cancer research (Baltimore). 2003, Vol 63, Num 18, pp 5957-5961, issn 0008-5472, 5 p.Article

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumorsDOI, Toshihiko; OHTSU, Atsushi; FUSE, Nozomu et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 1, pp 227-235, issn 0344-5704, 9 p.Article

Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selectionLU, Jian-Feng; RASMUSSEN, Erik; KARLAN, Beth Y et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 5, pp 1135-1144, issn 0344-5704, 10 p.Article

The role of interleukin 1 in growth and metastasis of human cancer xenograftsELARAJ, Dina M; WEINREICH, David M; VARGHESE, Sheelu et al.Clinical cancer research. 2006, Vol 12, Num 4, pp 1088-1096, issn 1078-0432, 9 p.Article